NetworkNewsBreaks – Mizuho Securities Reiterates “Buy” Rating on Aerie Pharmaceuticals, Inc. (NASDAQ: AERI)
Mizuho Securities USA LLC has reiterated its ‘Buy’ rating and price target of $70 on shares of Aerie Pharmaceuticals, Inc.’s (NASDAQ: AERI) stock after a Mizuho analyst spoke with company management regarding recent updates. Aerie’s shares have been weak since the company announced that its FDA advisory committee meeting on Rhopressa is scheduled for October 20. The analyst believes the weak shares represent a buying opportunity for investors. Additionally, the analysts noted that they believe the majority of the discussion at the meeting with the FDA on Rhopressa will be regarding potential side effects rather than efficacy. For more information,…







